Statin use and risk of skin cancer - 14/03/18
, Wen-Qing Li, PhD d, e, Eunyoung Cho, PhD b, d, e, Gary C. Curhan, MD, ScD b, c, f, g, Abrar A. Qureshi, MD b, d, eAbstract |
Background |
Statins are among the most commonly used medications in the United States, and statin use is associated with increased risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). However, previous studies are limited by lack of adjustment for important confounders.
Objective |
Examine the relation between statins and skin cancer risk in the Nurses' Health Study and Health Professionals Follow-up Study.
Methods |
Cox proportional hazards regression was used to evaluate associations.
Results |
During follow-up (2000-2010), we documented 10,201 BCC, 1393 SCC, and 333 melanoma cases. History of high cholesterol level was not associated with risk of BCC (pooled multivariable-adjusted hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.00-1.09), SCC (HR, 0.95; 95% CI, 0.85-1.06), or melanoma (HR, 0.87; 95% CI, 0.64-1.19). Statin use was not associated with risk of BCC (HR, 1.04; 95% CI, 0.99-1.09]), SCC (HR, 1.08; 95% CI, 0.94-1.24), or melanoma (HR, 1.04; 95% CI, 0.78-1.38). There was a trend toward higher BCC risk with longer duration of statin use in men (P trend = .003) but not in women (P trend = .86).
Limitations |
Lack of treatment data.
Conclusion |
History of high cholesterol level was not associated with skin cancer risk. Longer duration of statin use was associated with a trend toward higher BCC risk in men.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, epidemiology, high cholesterol, melanoma, squamous cell carcinoma, statins
Abbreviations used : BCC, HPFS, KC, MVRR, NHS, SCC
Plan
| Funding sources: Supported by National Institutes of Health grants for the Nurses' Health Study (UM1 CA186107 and P01 CA87969) and the Health Professionals Follow-up Study (UM1 CA167552) and the Research Career Development Award of Dermatology Foundation (to WL). The sponsors of this study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. |
|
| Disclosure: Dr Qureshi has received honoraria from AbbVie, Amgen, the Centers for Disease Control and Prevention, Janssen, Merck, Pfizer, and Novartis (as a consultant), and he is an investigator (without financial compensation) for Sanofi and Regeneron. Drs Lin, Li, Cho, and Curhan have no conflicts of interest to disclosed. |
Vol 78 - N° 4
P. 682-693 - avril 2018 Retour au numéro
Article précédent
- Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark
- Sidsel Arnspang Pedersen, David Gaist, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Hölmich, Søren Friis, Anton Pottegård
- Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes
- Chin-Hsiao Tseng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?